Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04TIJ
|
|||
| Former ID |
DIB015955
|
|||
| Drug Name |
Namitecan
|
|||
| Synonyms |
ST-1968; ST-1976; ST-2649; ST-2724; ST-3280; ST-3833; ST-4167; ST-4215; ST-5548; Peptide-camptothecin conjugates (cancer); Topoisomerase I inhibiting camptothecin analog (cancer), Sigma-Tau; Topoisomerase I inhibitor (cancer), Sigma-Tau; Peptide-camptothecin conjugates (cancer), Sigma-Tau
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Company |
Sigma-Tau Ind Farm Riunite SpA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H22N4O5
|
|||
| Canonical SMILES |
CCC1(C2=C(COC1=O)C(=O)N3CC4=C(C5=CC=CC=C5N=C4C3=C2)C=NOCCN)O
|
|||
| InChI |
1S/C23H22N4O5/c1-2-23(30)17-9-19-20-15(11-27(19)21(28)16(17)12-31-22(23)29)14(10-25-32-8-7-24)13-5-3-4-6-18(13)26-20/h3-6,9-10,30H,2,7-8,11-12,24H2,1H3/b25-10+/t23-/m0/s1
|
|||
| InChIKey |
IBTISPLPBBHVSU-UVOOVGFISA-N
|
|||
| CAS Number |
CAS 372105-27-6
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | DNA topoisomerase I (TOP1) | Target Info | Inhibitor | [2] |
| NetPath Pathway | IL2 Signaling Pathway | |||
| Panther Pathway | DNA replication | |||
| Pathway Interaction Database | Caspase Cascade in Apoptosis | |||
| WikiPathways | Integrated Pancreatic Cancer Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01748019) ST1968 Intravenous (Weekly) in Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | Namitecan: a hydrophilic camptothecin with a promising preclinical profile. Curr Med Chem. 2012;19(21):3488-501. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.